 |
The Comorbid Relationship of Hypogonadism and Type 2 Diabetes Mellitus in the Aging Male CME John E. Morley, MB, BCh, Chair; Sandeep S. Dhindsa, MD Author Information and Disclosures Release Date: April 3, 2008; Valid for credit through April 3, 2009 | Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at "The Comorbid Relationship of Hypogonadism and Type 2 Diabetes Mellitus in the Aging Male" symposium held at the Tampa Convention Center in Tampa, Florida, on February 22, 2008.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Imedex®, LLC. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Discuss and elucidate the pathogenesis of type 2 diabetes in patients with hypogonadotropic hypogonadism.
- Evaluate and discuss the clinical presentation of
patients with hypogonadotropic hypogonadism.
- Review and implement treatment plans for patients with the comorbidities of type 2 diabetes and hypogonadotropic hypogonadism.
Author Disclosures John E. Morley, MB, BCh
Disclosure: Grant/Research Support:
Baxter, Numico; Consultant: Amgen, Edunn Biotec, Indevus, Mattern Pharmaceuticals, Novartis; Speakers' Bureau: Amgen, GTx, Indevus, Mattern Pharmaceuticals, Merck & Co, Novartis, Novartis Nutritional, Orthobiotec; Stock Shareholder: Edunn Biotec, Mattern Pharmaceuticals
Sandeep S. Dhindsa, MD
Disclosure: Grant/Research Support: Solvay Pharmaceuticals, Speaker's Bureau: Solvay Pharmaceuticals
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer
and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Bradley Bongiovanni, ND, Becky Lynch, RN, and Kenneth Richardson, MD, own stock options for AmerisourceBergen.
|
 |
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
